WO2003087109A1 - Medicaments contenant des derives de glycerophosphoinositol-4-phosphate - Google Patents

Medicaments contenant des derives de glycerophosphoinositol-4-phosphate Download PDF

Info

Publication number
WO2003087109A1
WO2003087109A1 PCT/IB2002/001198 IB0201198W WO03087109A1 WO 2003087109 A1 WO2003087109 A1 WO 2003087109A1 IB 0201198 W IB0201198 W IB 0201198W WO 03087109 A1 WO03087109 A1 WO 03087109A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pathologies
use according
compounds
cation
Prior art date
Application number
PCT/IB2002/001198
Other languages
English (en)
Inventor
Cesare Biagi
Original Assignee
Silbiotec Due S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silbiotec Due S.A. filed Critical Silbiotec Due S.A.
Priority to AU2002253441A priority Critical patent/AU2002253441A1/en
Priority to PCT/IB2002/001198 priority patent/WO2003087109A1/fr
Publication of WO2003087109A1 publication Critical patent/WO2003087109A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Abstract

L'invention concerne les composés représentés par la formule générale (I) : (I), leurs énantiomères, diastéréoisomères, racémiques, les mélanges de ceux-ci, leurs hydrates et leurs solvates. R1, R2, R3, R4, R5, R6 et M ont les significations indiquées dans le descriptif. L'invention concerne également des compositions contenant ces composés, utilisables en tant que médicaments.
PCT/IB2002/001198 2002-04-12 2002-04-12 Medicaments contenant des derives de glycerophosphoinositol-4-phosphate WO2003087109A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002253441A AU2002253441A1 (en) 2002-04-12 2002-04-12 Medicaments containing glycerophosphoinositol-4-phosphate derivatives
PCT/IB2002/001198 WO2003087109A1 (fr) 2002-04-12 2002-04-12 Medicaments contenant des derives de glycerophosphoinositol-4-phosphate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/001198 WO2003087109A1 (fr) 2002-04-12 2002-04-12 Medicaments contenant des derives de glycerophosphoinositol-4-phosphate

Publications (1)

Publication Number Publication Date
WO2003087109A1 true WO2003087109A1 (fr) 2003-10-23

Family

ID=29227344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/001198 WO2003087109A1 (fr) 2002-04-12 2002-04-12 Medicaments contenant des derives de glycerophosphoinositol-4-phosphate

Country Status (2)

Country Link
AU (1) AU2002253441A1 (fr)
WO (1) WO2003087109A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059052A2 (fr) 2004-12-02 2006-06-08 Cis Bio International Derives de l'inositol-phosphate et procede de detection de l'inositol-1-phosphate
JP2009500319A (ja) * 2005-06-30 2009-01-08 ルカ、マリア デ フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法
WO2009038533A1 (fr) * 2007-09-17 2009-03-26 Bioneris Ab Procédé et moyens pour le traitement de la cachexie
ITRM20120473A1 (it) * 2012-10-04 2014-04-05 Consiglio Nazionale Ricerche Use of glycerophosphoinositols for the treatment of septic shock
JP2015502950A (ja) * 2011-12-08 2015-01-29 ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ 新規な脂肪生成阻害剤化合物
WO2018016645A1 (fr) * 2016-07-22 2018-01-25 国立大学法人秋田大学 Nouveau phospholipide et ses utilisations ainsi que développement d'un procédé de mesure de séparation de phospholipides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955453A (en) * 1998-04-24 1999-09-21 The Regents Of The University Of California Membrane-permeant phosphoinositides
US6258375B1 (en) * 1998-03-05 2001-07-10 Abbott Laboratories Antibacterial phosphoinositides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258375B1 (en) * 1998-03-05 2001-07-10 Abbott Laboratories Antibacterial phosphoinositides
US5955453A (en) * 1998-04-24 1999-09-21 The Regents Of The University Of California Membrane-permeant phosphoinositides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERRIE C P ET AL: "MEMBRANE TRANSPORT AND IN VITRO METABOLISM OF THE RAS CASCADE MESSENGER, GLYCEROPHOSPHOINOSITOL 4-PHOSPHATE", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 266, no. 2, 1 December 1999 (1999-12-01), pages 413 - 419, XP001011370, ISSN: 0014-2956 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178704B2 (en) 2004-12-02 2012-05-15 Cis Bio International Inositol-phosphate derivatives and method of detecting inositol-1-phosphate
FR2878850A1 (fr) * 2004-12-02 2006-06-09 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
WO2006059052A3 (fr) * 2004-12-02 2006-10-05 Cis Bio Int Derives de l'inositol-phosphate et procede de detection de l'inositol-1-phosphate
WO2006059052A2 (fr) 2004-12-02 2006-06-08 Cis Bio International Derives de l'inositol-phosphate et procede de detection de l'inositol-1-phosphate
JP2009500319A (ja) * 2005-06-30 2009-01-08 ルカ、マリア デ フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法
JP2010235616A (ja) * 2005-06-30 2010-10-21 Luca Maria De フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法
WO2009038533A1 (fr) * 2007-09-17 2009-03-26 Bioneris Ab Procédé et moyens pour le traitement de la cachexie
JP2015502950A (ja) * 2011-12-08 2015-01-29 ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ 新規な脂肪生成阻害剤化合物
ITRM20120473A1 (it) * 2012-10-04 2014-04-05 Consiglio Nazionale Ricerche Use of glycerophosphoinositols for the treatment of septic shock
WO2014053642A1 (fr) 2012-10-04 2014-04-10 Consiglio Nazionale Delle Ricerche Utilisation de glycérophosphoinositols pour le traitement d'un choc infectieux
US9351983B2 (en) 2012-10-04 2016-05-31 Consiglio Nazionale Delle Ricerche Use of glycerophosphoinositols for the treatment of septic shock
WO2018016645A1 (fr) * 2016-07-22 2018-01-25 国立大学法人秋田大学 Nouveau phospholipide et ses utilisations ainsi que développement d'un procédé de mesure de séparation de phospholipides
JPWO2018016645A1 (ja) * 2016-07-22 2019-06-13 国立大学法人秋田大学 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発

Also Published As

Publication number Publication date
AU2002253441A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
WO2006091905A1 (fr) Derives de bicyclo(3.1.0) hexane utilises comme composes antiviraux
EA030068B1 (ru) Соединения-ингибиторы аутотаксина
CA2945404A1 (fr) Analogues de bisphosphonates d'oxysterol osteogeniques ciblant specifiquement l'os
CA2427352C (fr) Derives de glycerophosphoinositol utilises comme modulateurs de la phospholipase cytosolique
JP6568536B2 (ja) パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法
CA3101626A1 (fr) Cannabinoides et leurs utilisations
US4619938A (en) Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors
CN111712491A (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2003087109A1 (fr) Medicaments contenant des derives de glycerophosphoinositol-4-phosphate
US5244917A (en) Substituted naphthofurans as anti-inflammatory agents
CN115427396A (zh) 用于预防或治疗脂质代谢相关疾病的化合物
US4550186A (en) Binuclear copper (II) carboxylates formed from amine-carboxyboranes
DE69907720T2 (de) Phospholipid-derivate von nichtsteroiden entzündungshemmenden medikamenten
EP4306528A1 (fr) Agent de dégradation à petite molécule hemtac et utilisation associée
JP3298881B2 (ja) （３ｓ，４ｓ）−デルタ−６−テトラヒドロカンナビノール−７−酸及びそれらの誘導体並びにそれらの合成方法並びにそれらを含む医薬組成物
US9085593B2 (en) Therapeutic agent for arthrosis
JP2004010582A (ja) カルバ環状ホスファチジン酸誘導体
JP5819865B2 (ja) 小腸刷子縁膜ナトリウム／リン酸塩共−輸送のアリールフルオロホスフェート阻害剤
WO2019196953A1 (fr) Inhibiteurs de ntcp
AU2014379612A1 (en) Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
NZ523990A (en) Prodrugs to NMDA receptor ligands
Dong et al. Synthesis and bioevaluation of Scutellarein-Tertramethylpyrazine hybrid molecules for the treatment of ischemic stroke
JP2005075834A (ja) 神経変性疾患の処置
JP5670858B2 (ja) サイトゾルのホスホリパーゼのモジュレーターとしてのグリセロホスホイノシトール誘導体
CN108276354B (zh) Tlr4/md2抑制剂及其在抗炎药物中的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP